Pacira Biosciences, Stock Today
| PCRX Stock | USD 16.91 0.27 1.62% |
Performance6 of 100
| Odds Of DistressLess than 29
|
Pacira BioSciences, is trading at 16.91 as of the 30th of November 2024; that is 1.62% up since the beginning of the trading day. The stock's open price was 16.64. Pacira BioSciences, has about a 29 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Note, on June 23, 2021, Representative Tom Malinowski of US Congress acquired under $15k worth of Pacira BioSciences,'s common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of February 2011 | Category Healthcare | Classification Health Care |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. The company has 46.17 M outstanding shares of which 4.82 M shares are at this time shorted by private and institutional investors with about 8.8 trading days to cover. More on Pacira BioSciences,
Moving against Pacira Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Pacira Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Frank Lee | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPacira BioSciences, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pacira BioSciences,'s financial leverage. It provides some insight into what part of Pacira BioSciences,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pacira BioSciences, (PCRX) is traded on NASDAQ Exchange in USA. It is located in 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609 and employs 711 people. Pacira BioSciences, is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 780.79 M. Pacira BioSciences, conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 46.17 M outstanding shares of which 4.82 M shares are at this time shorted by private and institutional investors with about 8.8 trading days to cover.
Pacira BioSciences, currently holds about 316.39 M in cash with 154.65 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.9.
Check Pacira BioSciences, Probability Of Bankruptcy
Ownership AllocationThe majority of Pacira BioSciences, outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pacira BioSciences, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pacira BioSciences,. Please pay attention to any change in the institutional holdings of Pacira BioSciences, as this could imply that something significant has changed or is about to change at the company. On June 23, 2021, Representative Tom Malinowski of US Congress acquired under $15k worth of Pacira BioSciences,'s common stock.
Check Pacira Ownership Details
Pacira Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 971.1 K | |
| Rock Springs Capital Management Lp | 2024-06-30 | 785 K | |
| Nuveen Asset Management, Llc | 2024-06-30 | 711.2 K | |
| Hhg Plc | 2024-06-30 | 698.4 K | |
| Schroder Investment Management Group | 2024-06-30 | 616.8 K | |
| Jpmorgan Chase & Co | 2024-06-30 | 600.6 K | |
| Bank Of America Corp | 2024-06-30 | 559 K | |
| Cubist Systematic Strategies, Llc | 2024-09-30 | 554.4 K | |
| Assenagon Asset Management Sa | 2024-09-30 | 553.1 K | |
| Blackrock Inc | 2024-06-30 | 8 M | |
| Vanguard Group Inc | 2024-09-30 | 5.3 M |
Pacira BioSciences, Historical Income Statement
Pacira Stock Against Markets
Pacira BioSciences, Corporate Management
| Richard Kahr | Vice Resources | Profile | |
| Daryl Gaugler | Chief Officer | Profile | |
| Charles Laranjeira | Chief Technical Officer | Profile | |
| Christopher Young | Chief Officer | Profile | |
| Shawn Cross | Chief Officer | Profile | |
| DO Ellis | Chief Officer | Profile | |
| III CPA | Chief Officer | Profile |
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.